Macrophages contribute to joint inflammation in RA by a number of functions. The typeI IgG receptor (FcγRI) has been shown to be upregulated on inflammatory macrophages and can very efficiently endocytose FcγRI-targeted antigens. Based on its unique function and distribution it was tried to selectively eliminate inflammatory macrophages by a FcγRI-directed humanized antibody (H22) conjugated to the toxin Ricin A (anti-FcγRI-RiA).

FcγRI expression (CD64) was determined on RA monocytes/ macrophages (mo/mac\'s) and granulocytes from peripheral blood (PB) and synovial fluid (SF). Anti-FcγRI-RiA was tested on mo/mac\'s from PB and SF of 12 RA patients. Cell death of mo/mac\'s (vs. lymphocytes) was assessed by morphological changes, changes in CD14 expression and nuclear DNA fragmentation (measuring apoptosis) after 24 hours. The anti-inflammatory effect *in vitro* was tested by the effect of anti-FcγRI-RiA on TNFα production, antigen-induced Th1-mediated proliferation and T-cell survival in the context of SFMC. In addition the effect on cytokine production by synovial tissue explants was studied (n = 6).

FcγRI was exclusively expressed on mo/mac\'s and was higher in SF than PB (MFI 232 vs. 59, *P* \< 0.01). Treatment with anti-FcγRI-RiA reduced high FcγRI-expressing mo/mac\'s and was associated and was associated by selective cell death of mo/mac\'s (death of lymphocytes was not observed after 24 hours). Immunotoxin-induced cell death was higher in SF than in PB (15% in PB vs. 61% in SF, *P* \< 0.01). High expression of FcγRI correlated with increased capacity of anti-FcγRI to induce mo/mac cell death. Induction of macrophage cell death was mediated via apoptosis as measured by nuclear DNA fragmentation. After prolonged culture (3--5 days) macrophage death was associated with significant reductions in TNFα production, Th1-induced lymphocyte proliferation and T-cell survival in the context of SFMC (42%, 63%, 72%, respectively). Furthermore, IL-1 production by RA synovial tissue explants was inhibited (63%, *P* \< 0.01). Macrophages from RA patients can be selectively eliminated by FcγRI-directed immunotoxins. Considering the important role of these cells in RA, this type of elimination may be a novel concept in the treatment of RA.
